Shop by goal
Popular compounds
Research resources
Recently viewed
Cagrilintide: Metabolic / Fat Loss research guide
Not medical advice. Cagrilintide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
What Cagrilintide is
Cagrilintide (AM833) is a long-acting acylated amylin analogue engineered for once-weekly dosing, with an ~8-day half-life and complementary appetite-suppression mechanism to GLP-1 receptor agonists.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research.
Research contexts
Peer-reviewed literature typically discusses Cagrilintide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Typical study contexts
Why Metabolic / Fat Loss research matters
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Mechanisms (technical review)
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Lab handling & preparation
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 0.25–2.4 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ = 159–195 h (~8 days); Tmax = 24–72 h (median); albumin binding via C20 fatty diacid (analogous to Semaglutide); dose escalation: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each maintained 4 weeks. CagriSema uses co-formulated 2.4/2.4 mg in single injection. Currently in late-phase clinical trials.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Common Questions People Are Asking
What is cagrilintide and how does it work?
Cagrilintide (AM833) is a long-acting, acylated analogue of the pancreatic hormone amylin. It is a non-selective agonist of the three amylin receptor subtypes (AMY1/2/3R) plus the calcitonin receptor, and acts on arcuate-nucleus appetite neurons to suppress hunger while delaying gastric emptying and lowering postprandial glucagon. A C20 fatty-diacid anchor binds serum albumin to extend its half-life to roughly eight days, supporting once-weekly research dosing.
How is cagrilintide different from a GLP-1 agonist?
GLP-1 agonists activate the GLP-1 receptor. Cagrilintide activates the amylin receptor family (AMY1/2/3R) plus the calcitonin receptor. The two pathways engage different appetite circuits, which is why combining them (as in CagriSema research) produces larger effects than either alone.
What does the research on cagrilintide actually show?
A Phase 2 dose-finding trial (Lancet 2021) reported dose-dependent body-weight reduction with cagrilintide monotherapy. In the Phase 3 REDEFINE 1 trial (NEJM 2025), the cagrilintide + semaglutide combination (CagriSema) reported a 20.4% mean reduction versus 3.0% placebo at 68 weeks on the treatment-policy estimand, with cagrilintide alone around 11.5% and semaglutide alone around 14.9%. These are descriptive clinical-trial findings, not outcomes promised for any use of this research-grade material.
Cagrilintide vs semaglutide — what is the difference?
They act through entirely different hormone systems: semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin/calcitonin-receptor agonist. Their half-lives are similar (cagrilintide ~159–195 h, semaglutide ~145–165 h), both supporting once-weekly dosing. In the REDEFINE programme the two were studied together precisely because their satiety pathways are additive rather than redundant.
What side effects were observed in cagrilintide studies?
The most frequently reported events in published trials were gastrointestinal — nausea, vomiting, decreased appetite, constipation or diarrhoea — that were typically mild-to-moderate, escalation-related and transient, plus injection-site reactions. Gallbladder events have been noted in combination research. These are observations recorded in the clinical literature, not a safety profile for any human use of this research material.
Why is the anti-fibrillation design important?
Native human amylin forms amyloid fibrils that are toxic to pancreatic islet cells and make the peptide impractical for sustained research use. Substituting prolines at positions 25, 28, and 29 (borrowed from rat amylin, which does not aggregate) blocks the fibrillation pathway.
How is cagrilintide reconstituted and stored?
Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water by directing it down the vial wall rather than onto the powder, then swirl gently — do not shake. After reconstitution, refrigerate at 1–6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty-acid tail.
Is cagrilintide approved or legal?
Cagrilintide is an investigational compound and is not an approved medicine on its own; the CagriSema combination remains in late-phase clinical development. The material supplied here is unapproved, research-grade laboratory material sold strictly for in-vitro and preclinical research use only — not for human use.
What happens if you stop taking peptides?
It depends on the peptide class. Cagrilintide is a long-acting amylin analogue studied for appetite and metabolic research, often alongside GLP-1 peptides. As with the GLP-1 class, the research literature on appetite-regulating peptides indicates the appetite effects depend on continued receptor stimulation, so they wane once administration stops and the compound clears; cagrilintide's long half-life means that clearance is gradual. These observations come from research and clinical studies — cagrilintide here is an unapproved research-grade peptide for laboratory research only and not for human use.
Is this page medical advice? Can I use Cagrilintide for my health?
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Where do I find Cagrilintide specs, purity certificates and pricing?
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Related peptide guides
Other compounds researchers often read about alongside Cagrilintide.
Scientific sources & further reading
Primary literature and registries for Cagrilintide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Ready to order? View full product specs
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Cagrilintide, Cagrilintide Acetate, Long-Acting Amylin Analogue, Amylin Analogue Research Peptide
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io